Provident Clinical Research/Biofortis North America, 489 Taft Avenue, Glen Ellyn, IL 60137, USA.
Int J Food Sci Nutr. 2012 Jun;63(4):476-82. doi: 10.3109/09637486.2011.636345. Epub 2011 Nov 17.
This randomized, placebo-controlled, crossover trial assessed the lipid-altering efficacy of a dietary supplement (tablet form) providing 1.8 g/day free (non-esterified) plant sterols and stanols versus placebo for 6 weeks as part of a therapeutic lifestyle changes (TLC) diet in 32 men and women with primary hypercholesterolaemia. Mean ± SE baseline (end of a 5-week TLC diet lead-in) lipid concentrations (mmol/l) were total cholesterol (TC), 5.88 ± 0.08; non-high-density lipoprotein cholesterol (non-HDL-C), 4.71 ± 0.09; low-density lipoprotein cholesterol (LDL-C), 4.02 ± 0.08; HDL-C, 1.17 ± 0.06 and triglycerides (TGs), 1.51 ± 0.12. Differences from control in responses (plant sterol/stanol - control) were significant (p < 0.05) for LDL-C ( - 4.9%), non-HDL-C ( - 3.6%) and TC ( - 2.8%). HDL-C and TG responses were not significantly different between treatment conditions. These results indicate that 1.8 g/day free plant sterols/stanols administered in a tablet produced favourable lipoprotein lipid changes in men and women with hypercholesterolaemia.
这项随机、安慰剂对照、交叉试验评估了一种饮食补充剂（片剂形式）的降脂效果，该补充剂提供 1.8 克/天的游离（非酯化）植物甾醇和甾烷醇，与安慰剂相比，作为治疗性生活方式改变（TLC）饮食的一部分，在 32 名患有原发性高胆固醇血症的男性和女性中使用 6 周。平均± SE 基线（5 周 TLC 饮食导入期结束时）脂质浓度（mmol/l）为总胆固醇（TC），5.88±0.08；非高密度脂蛋白胆固醇（非-HDL-C），4.71±0.09；低密度脂蛋白胆固醇（LDL-C），4.02±0.08；高密度脂蛋白胆固醇（HDL-C），1.17±0.06 和甘油三酯（TGs），1.51±0.12。与对照组相比，LDL-C（-4.9%）、非-HDL-C（-3.6%）和 TC（-2.8%）的反应差异具有统计学意义（p<0.05）。HDL-C 和 TG 的反应在治疗条件之间没有显著差异。这些结果表明，每天 1.8 克的游离植物甾醇/甾烷醇在片剂中给药，可使高胆固醇血症男性和女性的脂蛋白脂质发生有利变化。
